Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07232953 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia

Study acronym: FT14
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 18, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This is a prospective, multicenter, phase II, open-label, non-randomized clinical trial designed to evaluate the safety and efficacy of the Fludarabine plus Treosulfan 14 g/m² (FT14) conditioning regimen for allogeneic stem cell transplantation (allo-SCT) in patients with Acute Myeloid Leukemia (AML) aged 40-65 years who are in complete remission.
Trial Details
NCT Number NCT07232953
Lead Sponsor Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Conditions
(from sponsor)		 Acute Myeloid Leukaemia (AML), Hematopoietic Stem Cell Transplant (HSCT)
Related terms Leukemia, Myeloid, Acute
Enrollment 82 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov